 | • レポートコード：MRC2312MG00707 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の血友病治療薬市場規模と予測を収録しています。・世界の血友病治療薬市場：売上、2018年-2023年、2024年-2029年 ・世界の血友病治療薬市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の血友病治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「血液製品」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 血友病治療薬のグローバル主要企業は、Bayer、 Pfizer、 Novo Nordisk、 Takeda Pharmaceutical、 CSL Behring、 Sanofi、 Octapharma、 Grifols、 BioMarin Pharmaceutical、 Roche、 Bio Products Laboratory (BPL)、 Kedrion Biopharma、 LFB Group、 HuaLan Bio、 Shanghai RAAS、 Gensciencesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、血友病治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の血友病治療薬市場：タイプ別、2018年-2023年、2024年-2029年 世界の血友病治療薬市場：タイプ別市場シェア、2022年 ・血液製品、遺伝子組み換え製品 世界の血友病治療薬市場：用途別、2018年-2023年、2024年-2029年 世界の血友病治療薬市場：用途別市場シェア、2022年 ・血友病A、血友病B 世界の血友病治療薬市場：地域・国別、2018年-2023年、2024年-2029年 世界の血友病治療薬市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における血友病治療薬のグローバル売上、2018年-2023年 ・主要企業における血友病治療薬のグローバル売上シェア、2022年 ・主要企業における血友病治療薬のグローバル販売量、2018年-2023年 ・主要企業における血友病治療薬のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Bayer、 Pfizer、 Novo Nordisk、 Takeda Pharmaceutical、 CSL Behring、 Sanofi、 Octapharma、 Grifols、 BioMarin Pharmaceutical、 Roche、 Bio Products Laboratory (BPL)、 Kedrion Biopharma、 LFB Group、 HuaLan Bio、 Shanghai RAAS、 Gensciences ************************************************************* ・調査・分析レポートの概要 血友病治療薬市場の定義 市場セグメント 世界の血友病治療薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の血友病治療薬市場規模 世界の血友病治療薬市場規模：2022年 VS 2029年 世界の血友病治療薬市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの血友病治療薬の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の血友病治療薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：血液製品、遺伝子組み換え製品 血友病治療薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：血友病A、血友病B 血友病治療薬の用途別グローバル売上・予測 ・地域別市場分析 地域別血友病治療薬市場規模 2022年と2029年 地域別血友病治療薬売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Bayer、 Pfizer、 Novo Nordisk、 Takeda Pharmaceutical、 CSL Behring、 Sanofi、 Octapharma、 Grifols、 BioMarin Pharmaceutical、 Roche、 Bio Products Laboratory (BPL)、 Kedrion Biopharma、 LFB Group、 HuaLan Bio、 Shanghai RAAS、 Gensciences ... |
This research report provides a comprehensive analysis of the Hemophilia Medication market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Hemophilia Medication market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Hemophilia Medication, challenges faced by the industry, and potential opportunities for market players.
The global Hemophilia Medication market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Hemophilia Medication market presents opportunities for various stakeholders, including Hemophilia A, Hemophilia B. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Hemophilia Medication market. Additionally, the growing consumer demand present avenues for market expansion.
The global Hemophilia Medication market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Hemophilia Medication market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Hemophilia Medication market.
Market Overview: The report provides a comprehensive overview of the Hemophilia Medication market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Blood Products, Genetically Engineered Product), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Hemophilia Medication market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Hemophilia Medication market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Hemophilia Medication market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Hemophilia Medication market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Hemophilia Medication market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Hemophilia Medication market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Hemophilia Medication, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Hemophilia Medication market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Hemophilia Medication market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Blood Products
Genetically Engineered Product
Market segment by Application
Hemophilia A
Hemophilia B
Global Hemophilia Medication Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Bayer
Pfizer
Novo Nordisk
Takeda Pharmaceutical
CSL Behring
Sanofi
Octapharma
Grifols
BioMarin Pharmaceutical
Roche
Bio Products Laboratory (BPL)
Kedrion Biopharma
LFB Group
HuaLan Bio
Shanghai RAAS
Gensciences
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hemophilia Medication, market overview.
Chapter 2: Global Hemophilia Medication market size in revenue and volume.
Chapter 3: Detailed analysis of Hemophilia Medication manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hemophilia Medication in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Hemophilia Medication capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Hemophilia Medication Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hemophilia Medication Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hemophilia Medication Overall Market Size
2.1 Global Hemophilia Medication Market Size: 2022 VS 2029
2.2 Global Hemophilia Medication Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Hemophilia Medication Sales: 2018-2029
3 Company Landscape
3.1 Top Hemophilia Medication Players in Global Market
3.2 Top Global Hemophilia Medication Companies Ranked by Revenue
3.3 Global Hemophilia Medication Revenue by Companies
3.4 Global Hemophilia Medication Sales by Companies
3.5 Global Hemophilia Medication Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Hemophilia Medication Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Hemophilia Medication Product Type
3.8 Tier 1, Tier 2 and Tier 3 Hemophilia Medication Players in Global Market
3.8.1 List of Global Tier 1 Hemophilia Medication Companies
3.8.2 List of Global Tier 2 and Tier 3 Hemophilia Medication Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Hemophilia Medication Market Size Markets, 2022 & 2029
4.1.2 Blood Products
4.1.3 Genetically Engineered Product
4.2 By Type – Global Hemophilia Medication Revenue & Forecasts
4.2.1 By Type – Global Hemophilia Medication Revenue, 2018-2023
4.2.2 By Type – Global Hemophilia Medication Revenue, 2024-2029
4.2.3 By Type – Global Hemophilia Medication Revenue Market Share, 2018-2029
4.3 By Type – Global Hemophilia Medication Sales & Forecasts
4.3.1 By Type – Global Hemophilia Medication Sales, 2018-2023
4.3.2 By Type – Global Hemophilia Medication Sales, 2024-2029
4.3.3 By Type – Global Hemophilia Medication Sales Market Share, 2018-2029
4.4 By Type – Global Hemophilia Medication Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Hemophilia Medication Market Size, 2022 & 2029
5.1.2 Hemophilia A
5.1.3 Hemophilia B
5.2 By Application – Global Hemophilia Medication Revenue & Forecasts
5.2.1 By Application – Global Hemophilia Medication Revenue, 2018-2023
5.2.2 By Application – Global Hemophilia Medication Revenue, 2024-2029
5.2.3 By Application – Global Hemophilia Medication Revenue Market Share, 2018-2029
5.3 By Application – Global Hemophilia Medication Sales & Forecasts
5.3.1 By Application – Global Hemophilia Medication Sales, 2018-2023
5.3.2 By Application – Global Hemophilia Medication Sales, 2024-2029
5.3.3 By Application – Global Hemophilia Medication Sales Market Share, 2018-2029
5.4 By Application – Global Hemophilia Medication Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Hemophilia Medication Market Size, 2022 & 2029
6.2 By Region – Global Hemophilia Medication Revenue & Forecasts
6.2.1 By Region – Global Hemophilia Medication Revenue, 2018-2023
6.2.2 By Region – Global Hemophilia Medication Revenue, 2024-2029
6.2.3 By Region – Global Hemophilia Medication Revenue Market Share, 2018-2029
6.3 By Region – Global Hemophilia Medication Sales & Forecasts
6.3.1 By Region – Global Hemophilia Medication Sales, 2018-2023
6.3.2 By Region – Global Hemophilia Medication Sales, 2024-2029
6.3.3 By Region – Global Hemophilia Medication Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Hemophilia Medication Revenue, 2018-2029
6.4.2 By Country – North America Hemophilia Medication Sales, 2018-2029
6.4.3 US Hemophilia Medication Market Size, 2018-2029
6.4.4 Canada Hemophilia Medication Market Size, 2018-2029
6.4.5 Mexico Hemophilia Medication Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Hemophilia Medication Revenue, 2018-2029
6.5.2 By Country – Europe Hemophilia Medication Sales, 2018-2029
6.5.3 Germany Hemophilia Medication Market Size, 2018-2029
6.5.4 France Hemophilia Medication Market Size, 2018-2029
6.5.5 U.K. Hemophilia Medication Market Size, 2018-2029
6.5.6 Italy Hemophilia Medication Market Size, 2018-2029
6.5.7 Russia Hemophilia Medication Market Size, 2018-2029
6.5.8 Nordic Countries Hemophilia Medication Market Size, 2018-2029
6.5.9 Benelux Hemophilia Medication Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Hemophilia Medication Revenue, 2018-2029
6.6.2 By Region – Asia Hemophilia Medication Sales, 2018-2029
6.6.3 China Hemophilia Medication Market Size, 2018-2029
6.6.4 Japan Hemophilia Medication Market Size, 2018-2029
6.6.5 South Korea Hemophilia Medication Market Size, 2018-2029
6.6.6 Southeast Asia Hemophilia Medication Market Size, 2018-2029
6.6.7 India Hemophilia Medication Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Hemophilia Medication Revenue, 2018-2029
6.7.2 By Country – South America Hemophilia Medication Sales, 2018-2029
6.7.3 Brazil Hemophilia Medication Market Size, 2018-2029
6.7.4 Argentina Hemophilia Medication Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Hemophilia Medication Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Hemophilia Medication Sales, 2018-2029
6.8.3 Turkey Hemophilia Medication Market Size, 2018-2029
6.8.4 Israel Hemophilia Medication Market Size, 2018-2029
6.8.5 Saudi Arabia Hemophilia Medication Market Size, 2018-2029
6.8.6 UAE Hemophilia Medication Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Bayer
7.1.1 Bayer Company Summary
7.1.2 Bayer Business Overview
7.1.3 Bayer Hemophilia Medication Major Product Offerings
7.1.4 Bayer Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.1.5 Bayer Key News & Latest Developments
7.2 Pfizer
7.2.1 Pfizer Company Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Hemophilia Medication Major Product Offerings
7.2.4 Pfizer Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.2.5 Pfizer Key News & Latest Developments
7.3 Novo Nordisk
7.3.1 Novo Nordisk Company Summary
7.3.2 Novo Nordisk Business Overview
7.3.3 Novo Nordisk Hemophilia Medication Major Product Offerings
7.3.4 Novo Nordisk Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.3.5 Novo Nordisk Key News & Latest Developments
7.4 Takeda Pharmaceutical
7.4.1 Takeda Pharmaceutical Company Summary
7.4.2 Takeda Pharmaceutical Business Overview
7.4.3 Takeda Pharmaceutical Hemophilia Medication Major Product Offerings
7.4.4 Takeda Pharmaceutical Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.4.5 Takeda Pharmaceutical Key News & Latest Developments
7.5 CSL Behring
7.5.1 CSL Behring Company Summary
7.5.2 CSL Behring Business Overview
7.5.3 CSL Behring Hemophilia Medication Major Product Offerings
7.5.4 CSL Behring Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.5.5 CSL Behring Key News & Latest Developments
7.6 Sanofi
7.6.1 Sanofi Company Summary
7.6.2 Sanofi Business Overview
7.6.3 Sanofi Hemophilia Medication Major Product Offerings
7.6.4 Sanofi Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.6.5 Sanofi Key News & Latest Developments
7.7 Octapharma
7.7.1 Octapharma Company Summary
7.7.2 Octapharma Business Overview
7.7.3 Octapharma Hemophilia Medication Major Product Offerings
7.7.4 Octapharma Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.7.5 Octapharma Key News & Latest Developments
7.8 Grifols
7.8.1 Grifols Company Summary
7.8.2 Grifols Business Overview
7.8.3 Grifols Hemophilia Medication Major Product Offerings
7.8.4 Grifols Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.8.5 Grifols Key News & Latest Developments
7.9 BioMarin Pharmaceutical
7.9.1 BioMarin Pharmaceutical Company Summary
7.9.2 BioMarin Pharmaceutical Business Overview
7.9.3 BioMarin Pharmaceutical Hemophilia Medication Major Product Offerings
7.9.4 BioMarin Pharmaceutical Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.9.5 BioMarin Pharmaceutical Key News & Latest Developments
7.10 Roche
7.10.1 Roche Company Summary
7.10.2 Roche Business Overview
7.10.3 Roche Hemophilia Medication Major Product Offerings
7.10.4 Roche Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.10.5 Roche Key News & Latest Developments
7.11 Bio Products Laboratory (BPL)
7.11.1 Bio Products Laboratory (BPL) Company Summary
7.11.2 Bio Products Laboratory (BPL) Business Overview
7.11.3 Bio Products Laboratory (BPL) Hemophilia Medication Major Product Offerings
7.11.4 Bio Products Laboratory (BPL) Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.11.5 Bio Products Laboratory (BPL) Key News & Latest Developments
7.12 Kedrion Biopharma
7.12.1 Kedrion Biopharma Company Summary
7.12.2 Kedrion Biopharma Business Overview
7.12.3 Kedrion Biopharma Hemophilia Medication Major Product Offerings
7.12.4 Kedrion Biopharma Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.12.5 Kedrion Biopharma Key News & Latest Developments
7.13 LFB Group
7.13.1 LFB Group Company Summary
7.13.2 LFB Group Business Overview
7.13.3 LFB Group Hemophilia Medication Major Product Offerings
7.13.4 LFB Group Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.13.5 LFB Group Key News & Latest Developments
7.14 HuaLan Bio
7.14.1 HuaLan Bio Company Summary
7.14.2 HuaLan Bio Business Overview
7.14.3 HuaLan Bio Hemophilia Medication Major Product Offerings
7.14.4 HuaLan Bio Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.14.5 HuaLan Bio Key News & Latest Developments
7.15 Shanghai RAAS
7.15.1 Shanghai RAAS Company Summary
7.15.2 Shanghai RAAS Business Overview
7.15.3 Shanghai RAAS Hemophilia Medication Major Product Offerings
7.15.4 Shanghai RAAS Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.15.5 Shanghai RAAS Key News & Latest Developments
7.16 Gensciences
7.16.1 Gensciences Company Summary
7.16.2 Gensciences Business Overview
7.16.3 Gensciences Hemophilia Medication Major Product Offerings
7.16.4 Gensciences Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.16.5 Gensciences Key News & Latest Developments
8 Global Hemophilia Medication Production Capacity, Analysis
8.1 Global Hemophilia Medication Production Capacity, 2018-2029
8.2 Hemophilia Medication Production Capacity of Key Manufacturers in Global Market
8.3 Global Hemophilia Medication Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Hemophilia Medication Supply Chain Analysis
10.1 Hemophilia Medication Industry Value Chain
10.2 Hemophilia Medication Upstream Market
10.3 Hemophilia Medication Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Hemophilia Medication Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
